ライフサイエンスコーパス: New York Heart Association

1 2, patients in group 3 had a higher-rate of New York Heart Association 3 to 4 (26% versus 12% and 10

2 hundred ninety-eight HF patients (51% HFpEF, New York Heart Association 3.1+/-0.7) and 40 HF-free con

3 survival free of stroke, rehospitalization, New York Heart Association 3/4, and device-related dysfu

4 % had connective tissue disease, 52% were in New York Heart Association class >/=III, and mean pulmon

5 onfidence interval, 1.18-1.63 per 10 years), New York Heart Association class (1.60, 1.21-2.12 class

6 re (hazard ratio, 1.19; 1.13-1.27; P<0.001), New York Heart Association class (hazard ratio, 1.44; 1.

7 cal storm (hazard ratio, 3.211; P=0.001) and New York Heart Association class (hazard ratio, 1.608; P

8 gree of persisting leak (HR, 2.87; P=0.037), New York Heart Association class (HR, 2.00; P=0.015) at

9 Advanced New York Heart Association class (III and IV versus I an

10 F were older (67 versus 62 years), had worse New York Heart Association class (III/IV; 36% versus 24%

11 tation, there were sustained improvements in New York Heart Association class (P<0.001), quality of l

12 HNC patients improved more regarding New York Heart Association class (P=0.05), physical func

13 re no correlations between baseline IVSd and New York Heart Association class (P=0.067), Canadian Car

14 (86%) of 49 survivors in the TAVR group had New York Heart Association class 1 or 2 symptoms compare

15 The proportion of patients in New York Heart Association class 3 to 4 was reduced from

16 blation of PVC foci improves LV function and New York Heart Association class and promotes reverse re

17 rom 61 +/- 44 to 10 +/- 25 mm Hg (P<0.0001); New York Heart Association class decreased from 2.7 +/-

18 he substudy were patient preference (31.9%), New York Heart Association Class I (17.0%), and a QRS<15

19 At follow-up, 77% of patients were in New York Heart Association class I or II (P<0.001 versus

20 1).m(-2), 6-minute walk distance >440 m, and New York Heart Association class I or II functional clas

21 death, without mitral reintervention, and in New York Heart Association class I or II) was 2.5 (95% c

22 at percutaneous mitral commissurotomy and in New York Heart Association class I or II) was 30.2 +/- 2

23 Almost all patients were in New York Heart Association class I or II.

24 ve at 62+/-13 years of age, including 89% in New York Heart Association class I or II.

25 eft ventricular function, and all but 1 have New York Heart Association class I symptoms.

26 tion <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent

27 cular ejection fraction of 35% or lower, had New York Heart Association class I to IV heart failure,

28 an did HFrEF patients with low fatigability (New York Heart Association class I), despite similar lef

29 erquartile range, 25-41 years; 58% male; 90% New York Heart Association class I).

30 (mean age of 34 +/- 12 years, 57% male, 90% New York Heart Association class I).

31 rsus 8 days; P<0.0001), and slower recovery (New York Heart Association class I, 31% versus 38% at 30

32 raction <40 or >/= 40% (P-interaction=0.38), New York Heart Association class I-II versus III-IV (P-i

33 rviving patients had good functional status (New York Heart Association class I/II).

34 s functional capacity and quality of life in New York Heart Association class II and III CHF patients

35 on <50%, and only 11 (9%) were classified as New York Heart Association class II or higher.

36 58 years, most patients were male (83%) with New York Heart Association Class II or III (59%) heart f

37 controlled, multicenter study, patients with New York Heart Association Class II to III chronic heart

38 eft ventricular ejection fraction </=35% and New York Heart Association class II to III were randomly

39 of age with chronic chagasic cardiomyopathy, New York Heart Association class II to IV heart failure,

40 left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either e

41 sand three hundred ninety-nine patients with New York Heart Association class II to IV HF with reduce

42 CHARM enrolled 7599 patients with New York Heart Association class II to IV HF, of whom 54

43 Thirty-nine subjects with New York Heart Association class II to IV ischemic HF, e

44 Of 187 New York Heart Association class II to IV patients with

45 omly assigned 8399 patients with chronic HF, New York Heart Association class II to IV symptoms, and

46 (left ventricular ejection fraction 45% and New York Heart Association class II) and major depressiv

47 on fraction </=35%, QRS width >/=130 ms, and New York Heart Association class II, III, or ambulatory

48 affected, with 8.8% of all LSs classified as New York Heart Association class II, whereas more severe

49 Importantly, HFrEF New York Heart Association class II-III patients with EI

50 Data from 964 New York Heart Association class II-III subjects in ADMI

51 ry 2014, patients at outpatient clinics with New York Heart Association class II-IV heart failure and

52 High-risk ambulatory patients with New York Heart Association class II-IV symptoms of heart

53 h left ventricular ejection fraction >/=40%, New York Heart Association class II-IV, elevated pulmona

54 gating Outcomes of Exercise TraiNing) study (New York Heart Association class II-IV, left ventricular

55 pe (left ventricular ejection fraction <40%, New York Heart Association class II-IV, sinus rhythm, an

56 and total days in hospital in patients with New York Heart Association class II/III heart failure co

57 efibrillator with LVEF </=30% or </=35% with New York Heart Association class II/III heart failure we

58 ure (mean age 58 +/- 14 years, 46% male, 89% New York Heart Association class II/III).

59 as assessed by the percentage of patients in New York Heart Association class III and IV (90.1% to 7.

60 3 patients with ischemic cardiomyopathy with New York Heart Association class III and left ventricula

61 nitoring of Pressures to Improve Outcomes in New York Heart Association Class III Heart Failure Patie

62 nteen subjects with ischemic cardiomyopathy, New York Heart Association class III heart failure, with

63 , blinded multicenter trial in patients with New York Heart Association class III or ambulatory class

64 diagnosed with HF were included according to New York Heart Association class III or IV at admission

65 as associated with outcome, many patients in New York Heart Association class III or IV at baseline i

66 ptomatic congestive heart failure defined as New York Heart Association Class III or IV events occurr

67 -specific death risk in 75 079 patients with New York Heart Association class III or IV heart failure

68 evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure

69 patients from 31 sites in North America with New York Heart Association class III or IV symptomatic h

70 d, 5 within 30 days; all 22 patients were in New York Heart Association class III or IV, and 9 were h

71 d as symptomatic congestive heart failure of New York Heart Association class III or IV, confirmed by

72 ge was 40 years, and 71% of patients were in New York Heart Association class III or IV.

73 64 (+/-19) mL/min per 1.73 m(2), and 34% had New York Heart Association Class III symptoms.

74 up for 6.1+/-6.9 years after development of New York Heart Association class III to IV symptoms.

75 nal study enrolled 166 patients with chronic New York Heart Association class III-IV HF, ejection fra

76 9+/-11 years old, and 49% men, predominately New York Heart Association class III/IV status.

77 y of consecutive ambulant patients with CHF (New York Heart Association class III/IV) referred for as

78 ricular ejection fraction <35%; QRS >120 ms; New York Heart Association class III/IV) undergoing CRT

79 age: 82.4 years), severely symptomatic (87% New York Heart Association class III/IV), and at prohibi

80 ents, (67.6+/-12.1 years; 27.7% women; 42.3% New York Heart Association class III/IV).

81 Older age, obesity, current smoking, New York Heart Association class III/IV, and comorbid il

82 However, recent heart failure admission, New York Heart Association class III/IV, antiarrhythmic

83 omyopathy, more severe heart failure status (New York Heart Association class III/IV, lower ejection

84 Using multivariable analysis, New York Heart Association class III/IV, RVESRI, and log

85 ft ventricular ejection fraction </=35%, and New York Heart Association class III/IV.

86 3%; P=0.002); had more severe heart failure (New York Heart Association class III/IV: 55% versus 15%,

87 th symptomatic heart failure undergoing CRT (New York Heart Association class III/IV; QRS >120 millis

88 Mean New York Heart Association class improved from 2.7+/-0.8

89 summary scores were strongly associated with New York Heart Association class in both patients with H

90 04; P=0.039), female sex (HR=2.33; P=0.043), New York Heart Association class IV (HR=4.42; P=0.002),

91 lthough it is typically not considered among New York Heart Association class IV (NYHA IV) heart fail

92 0001), incremental age (OR, 1.05; P<0.0001), New York Heart Association class IV (OR, 1.33; P=0.02),

93 Both patients were in New York Heart Association class IV heart failure with d

94 Frailty was associated with New York Heart Association class IV heart failure, lower

95 African America race, New York Heart Association class IV symptoms, atrial fib

96 fractory heart failure, with median baseline New York Heart Association class IV, cardiac index of 1.

97 Heart Association class showing an impact of New York Heart Association class only in patients in atr

98 ection fraction, who were younger had higher New York Heart Association class or comorbid angina pect

99 r CRT whereas 19 (28.8%) showed no change in New York Heart Association class or worsened (nonrespond

100 r in men, and interaction between rhythm and New York Heart Association class showing an impact of Ne

101 unction, stable angina pectoris, or advanced New York Heart Association class symptoms.

102 Pre-operative New York Heart Association class was III or IV in 125 of

103 New York Heart Association class was significantly impro

104 dictors of survival, whereas LS and advanced New York Heart Association class were negative predictor

105 ter in patients with aortic stenosis and low New York Heart Association class with aortic regurgitati

106 S to clinical parameters (additive Euroscore+New York Heart Association class) led to significant imp

107 on width, diabetes mellitus, hemoglobin, and New York Heart Association class) strongly associated wi

108 ients with chronic HF (n=96, 76 +/- 9 years; New York Heart Association class, 2.9 +/- 0.8) and age-m

109 cel-T treatment was associated with improved New York Heart Association class, 6-minute walk distance

110 y end points were change in quality of life, New York Heart Association class, 6-minute walk distance

111 The associations between New York Heart Association class, a commonly used criter

112 t powerful predictors were older age, higher New York Heart Association class, and lower estimated gl

113 ctors of perforation were history of stroke, New York Heart Association class, and number of stents u

114 glycemic agent, lower activity level, higher New York Heart Association class, and selective serotoni

115 ed to a model that included age, chest pain, New York Heart Association class, and Westergren sedimen

116 were calcification extent, older age, higher New York Heart Association class, atrial fibrillation, a

117 Baseline IVSd was not correlated with New York Heart Association class, Canadian Cardiology So

118 Age, left ventricular ejection fraction, New York Heart Association class, chronic obstructive pu

119 ences identified in terms of study duration, New York Heart Association class, ejection fraction, and

120 ge, sex, left ventricular ejection fraction, New York Heart Association class, heart rate, and baseli

121 thickness and left atrial volume, and worse New York Heart Association class, HF-specific quality of

122 Chest pain, lower New York Heart Association class, higher Westergren sedi

123 s (lower body mass index, higher heart rate, New York Heart Association class, large QRS, and severe

124 es mellitus, rales, peripheral edema, higher New York Heart Association class, lower diastolic blood

125 of heart failure severity, including higher New York Heart Association class, lower systolic blood p

126 0.008) after correction for age, heart rate, New York Heart Association class, LV volumes, and LV and

127 ng with Heart Failure Questionnaire (MLHFQ), New York Heart Association class, LV volumes, ejection f

128 phic location, younger age, male sex, higher New York Heart Association class, worse HF knowledge, po

129 ycemic agent, more activity level, and lower New York Heart Association class.

130 Primary prevention had higher New York Heart Association class.

131 nontransvenous lead implants, CHD type, and New York Heart Association class.

132 6-minute walk distance, quality of life, and New York Heart Association class.

133 severe heart failure symptoms as measured by New York Heart Association class.

134 From 2 centers, 208 CRT candidates (New York Heart Association classes II to IV, ejection fr

135 luded patients with HF, aged >/=60 years, in New York Heart Association classes II to IV, who had isc

136 s and mild to moderate heart failure (96.8%; New York Heart Association, classes I-II) were enrolled.

137 alysis, early recurrence was associated with New York Heart Association classification >/=III (odds r

138 bo-controlled trial of symptomatic patients (New York Heart Association classification II-III or Cana

139 ts, 20 of 28 patients demonstrated preserved New York Heart Association classification status, but 15

140 For 22 of the 40 patients (55%), the New York Heart Association classification was class II a

141 Propensity scoring using New York Heart Association Classification was used to ma

142 New York Heart Association classification, 6-min walk te

143 atients presented with a significantly lower New York Heart Association clinical class and higher lef

144 +/- 14.3 years; 469 men [65.5%]; 577 [80.6%] New York Heart Association function class I/II), 83 (11.

145 dian; HR, 1.99; 95% CI, 1.32-3.04; P<0.001), New York Heart Association functional class >/=3 (HR, 1.

146 tients with TR presented with more symptoms (New York Heart Association functional class >/=II 55% vs

147 tion (ejection fraction <55%; p = 0.03), and New York Heart Association functional class >2 at diagno

148 ped risk score including 5 clinical factors (New York Heart Association functional class >II, age >70

149 pital readmission for heart failure and with New York Heart Association functional class </=II.

150 with RV LPSS >/=-19% had significantly worse New York Heart Association functional class (2.7+/-0.6 v

151 ml to 212 +/- 63 ml, p < 0.001), and median New York Heart Association functional class (3.0 to 2.0,

152 was associated with a greater improvement in New York Heart Association functional class (p < 0.0001)

153 Six-min walk distance (p = 0.2328) and New York Heart Association functional class (p = 0.1712)

154 (P<0.001), 6-minute walk distance (P=0.004), New York Heart Association functional class (P=0.009), r

155 C-treated patients displayed improvements of New York Heart Association functional class (P=0.0167 ve

156 EOV was associated with higher New York Heart Association functional class (P=0.02) and

157 The GLS worsened with increasing New York Heart Association functional class (rank-sum p

158 val: 0.24 to 0.81]), and improvement in mean New York Heart Association functional class (risk ratio:

159 int (defined as congestive heart failure >/= New York Heart Association functional class 3 or 30-d de

160 nts (mean age, 74.0 years; 54.9% men; 65.3%; New York Heart Association functional class 3 or 4), 164

161 stive heart failure greater than or equal to New York Heart Association functional class 3, poor left

162 hm was associated with beneficial effects on New York Heart Association functional class and modest g

163 New York Heart Association functional class and quality

164 total aortic valve regurgitation, and higher New York Heart Association functional class at 1 year.

165 Questionnaire score, 6-minute walk time, and New York Heart Association functional class at 6 months.

166 Over a 23 +/- 2 months follow-up, New York Heart Association functional class decreased fr

167 stable, normal left ventricular function and New York Heart Association functional class during the l

168 In HF patients in New York Heart Association functional class I and II and

169 32 patients with stage C HF who recovered to New York Heart Association functional class I at 6 and 1

170 Improvements in symptom class (79% in New York Heart Association functional class I or II at f

171 p of 15 +/- 4 months, symptom improvement to New York Heart Association functional class I or II occu

172 At 2 years, 94% of patients had New York Heart Association functional class I or II symp

173 s reported mild or no symptoms at follow-up (New York Heart Association functional class I or II).

174 e revised to include the following: modified New York Heart Association functional class I or II, 6-m

175 Current goals include achieving modified New York Heart Association functional class I or II, 6-m

176 mained MR </=2+ at 1 year, and 86.9% were in New York Heart Association functional class I or II.

177 At follow-up, all patients were in New York Heart Association functional class I.

178 n 3 centers (44 +/- 17 years; 66% male) with New York Heart Association functional class I/II symptom

179 48; 95% confidence interval, 0.05-4.59); and New York Heart Association functional class I/II was doc

180 ing stroke occurred in 2.5% of patients, and New York Heart Association functional class I/II was obs

181 All patients alive were in New York Heart Association functional class I/II with go

182 lity was 8.4%, and 84.1% of patients were at New York Heart Association functional class I/II.

183 Patients in New York Heart Association functional class II and with

184 At 12 months, 71.4% of patients had New York Heart Association functional class II or class

185 All patients were in New York Heart Association functional class II or less.

186 appeared to be harmed by amiodarone, whereas New York Heart Association functional class II patients

187 in patients with ejection fraction <35% and New York Heart Association functional class II to III HF

188 ge C heart failure (HF) (exertional dyspnea, New York Heart Association functional class II to III, e

189 age 67 +/- 9 years) with exertional dyspnea (New York Heart Association functional class II to III, l

190 lculated every 24 hours in 378 subjects with New York Heart Association functional class II-III heart

191 Ninety consecutive patients with HF, New York Heart Association functional class II-III, and

192 17 clinically stable male patients with CHF (New York Heart Association functional class II/III, left

193 71+/-11 years, 61% were men, and 97% were in New York Heart Association functional class II/III.

194 s), Hispanic (2 points), or other (1 point); New York Heart Association functional class III (1 point

195 On multivariable analysis, pre-procedure New York Heart Association functional class III and IV h

196 of patients (85.5%) were highly symptomatic (New York Heart Association functional class III or highe

197 p = 0.015); 2) higher rate of progression to New York Heart Association functional class III or IV (1

198 s mellitus (HR: 1.36; 95% CI: 1.13 to 1.64), New York Heart Association functional class III or IV (H

199 rillation (p < 0.001), dialysis (p < 0.001), New York Heart Association functional class III or IV (p

200 one Evaluation Study) in 1,658 patients with New York Heart Association functional class III or IV HF

201 ne was 23.0 +/- 18.3; 84.9% patients were in New York Heart Association functional class III or IV, a

202 score was 6.4 +/- 5.5%; 86% of patients were New York Heart Association functional class III or IV, a

203 ors of mortality included cardiac variables (New York Heart Association Functional Class III or IV, p

204 subgroup analysis showed that patients with New York Heart Association functional class III symptoms

205 centers including patients with chronic HF, New York Heart Association functional class III symptoms

206 interval [CI]: 1.62 to 1.79), heart failure (New York Heart Association functional class III) (HR: 1.

207 art failure symptoms due to obstructive HCM (New York Heart Association functional class III).

208 tio: 2.8; 95% CI: 1.3 to 6.9; p = 0.025) and New York Heart Association functional class III/IV (haza

209 heart failure (HR, 2.16; 95% CI, 1.70-2.72), New York Heart Association functional class III/IV (HR,

210 tances (56.5 +/- 92.0 m) and improvements in New York Heart Association functional class III/IV at 6

211 eplacement (8.34%), were highly symptomatic (New York Heart Association functional class III/IV in 82

212 ccurrence (the primary endpoint), defined as New York Heart Association functional class III/IV sympt

213 20 patients were 42+/-13 years old, each in New York Heart Association functional class III/IV with

214 tients (ejection fraction <35%, QRS >120 ms, New York Heart Association functional class III/IV) with

215 (age 82.7 +/- 5.5 years, 67.5% female, 68.0% New York Heart Association functional class III/IV).

216 7% of the patients were female, and 76% were New York Heart Association functional class III/IV.

217 timal medical management (OMM) in ambulatory New York Heart Association functional class IIIB/IV pati

218 New York Heart Association functional class improved fro

219 New York Heart Association functional class improved fro

220 0.91-0.95), hemodialysis (3.25; 2.42-4.37), New York Heart Association functional class IV (1.25; 1.

221 Mortality was associated with New York Heart Association functional class IV (hazard r

222 Multivariate analysis identified male sex, New York Heart Association functional class IV, and no p

223 tors for SVCs were female sex, pre-operative New York Heart Association functional class IV, ejection

224 New York Heart Association functional class or Ross clas

225 unction (echocardiography), clinical status (New York Heart Association functional class or Ross clas

226 Patients with worsened New York Heart Association functional class presented hi

227 vivors, there was significant improvement in New York Heart Association functional class sustained at

228 tomatic; a clear association between BNP and New York Heart Association functional class was demonstr

229 tive orifice area of 1.50 +/- 0.56 cm(2) and New York Heart Association functional class was I or II

230 On follow-up (153+/-94 days), New York Heart Association functional class was reduced

231 p of 47 months, organ involvement and higher New York Heart Association functional class were associa

232 ection fraction, 6-minute walk distance, and New York Heart Association functional class were recorde

233 linical variables (age, Karnofsky index, and New York Heart Association functional class) and serolog

234 At first follow-up RHC (n=763), New York Heart Association functional class, 6-minute wa

235 Contemporaneous clinical data included New York Heart Association functional class, 6-minute-wa

236 Quality of life, New York Heart Association functional class, and 6-min w

237 ignificantly lower exercise tolerance, worse New York Heart Association functional class, and higher

238 There was no change in 6-min walk test or New York Heart Association functional class, and levels

239 ended to have lower ejection fraction, worse New York Heart Association functional class, and lower u

240 fraction, time since first diagnosis of AF, New York Heart Association functional class, depression

241 with recurrent ICD shocks, whereas advanced New York Heart Association functional class, longer VT c

242 ventricular systolic and diastolic volumes, New York Heart Association functional class, Minnesota q

243 Greater inter-ventricular mechanical delay, New York Heart Association functional class, mitral regu

244 vascular hospitalization after adjusting for New York Heart Association functional class, peak VO2, a

245 compassing cardiac parameters in tandem with New York Heart Association functional class, quality of

246 = 0.004) to baseline predictors of survival (New York Heart Association functional class, wall motion

247 Survival, stroke, and New York Heart Association functional class.

248 diology/American Heart Association stage and New York Heart Association functional class.

249 rognosis independently of renal function and New York Heart Association functional class.

250 D=11), mostly (58%) male and mostly (77%) in New York Heart Association functional classes II and III

251 (10%) developed progressive heart failure to New York Heart Association functional classes III/IV.

252 BNP levels were related to New York Heart Association functional status (p < 0.0001

253 for age, QRS duration, atrial fibrillation, New York Heart Association heart failure class and blood

254 ment for left ventricular ejection fraction, New York Heart Association HF class, and implanted impla

255 azone is contraindicated in patients with HF>New York Heart Association I, despite some benefits sugg

256 iac resynchronization therapy defibrillator, New York Heart Association II to III, and left ventricul

257 left ventricular ejection fraction to <50%, New York Heart Association III or IV in the absence of o

258 Persistence of New York Heart Association III to IV classes, left atriu

259 monary hypertension, renal or liver disease, New York Heart Association III/IV symptoms, transaortic

260 kedown, conversion to extracardiac conduits, New York Heart Association III/IV, or protein-losing ent

261 ment and functional class as assessed by the New York Heart Association improved on FCM versus standa

262 redictors of troponin T increase were higher New York Heart Association (NYHA) class (NYHA I versus N

263 New York Heart Association (NYHA) class and echocardiogr

264 RS duration of 120 milliseconds or more, and New York Heart Association (NYHA) class I or II symptoms

265 ions for pacing with atrioventricular block; New York Heart Association (NYHA) class I, II, or III he

266 ion: Patients at an average age of 64 years, New York Heart Association (NYHA) class II to IV heart f

267 ble-blind multicentre trial in patients with New York Heart Association (NYHA) class II-III heart fai

268 Patients (aged >/=18 years) with New York Heart Association (NYHA) class III chronic hear

269 centre study that enrolled participants with New York Heart Association (NYHA) Class III heart failur

270 22 (96%) of 23 patients were New York Heart Association (NYHA) class III or IV at bas

271 (32.8% vs 41.3%; R(2) = 0.82), preoperative New York Heart Association (NYHA) class III or IV heart

272 n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and

273 by cardiopulmonary exercise testing (pkVO2), New York Heart Association (NYHA) classification, and us

274 ovember 2015 and June 2016, 15 patients with New York Heart Association (NYHA) functional class >/=II

275 Patients newly diagnosed with symptomatic New York Heart Association (NYHA) functional class >/=II

276 ariables, ranking biomarkers associated with New York Heart Association (NYHA) Functional class and t

277 t-related variables that are associated with New York Heart Association (NYHA) functional class and t

278 Post-procedural MR and New York Heart Association (NYHA) functional class at 1

279 ore was 3.98 +/- 1%; 54% of patients were in New York Heart Association (NYHA) functional class I and

280 e and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II an

281 All patients had severe TR and New York Heart Association (NYHA) functional class II to

282 all-cause mortality in 10,062 patients with New York Heart Association (NYHA) functional class III t

283 5% CI: 1.2 to 10.7, p = 0.02) for developing New York Heart Association (NYHA) functional class III t

284 L amyloidosis included sex, Karnofsky index, New York Heart Association (NYHA) functional class, dias

285 ection fraction, LV end-diastolic volume, or New York Heart Association (NYHA) functional class, yiel

286 as defined as an improvement by at least one New York Heart Association (NYHA) functional class.

287 assify the severity of heart failure are the New York Heart Association (NYHA) functional classificat

288 ementation on the ejection fraction (EF) and New York Heart Association (NYHA) functional classificat

289 score, quality of life (QOL), and change in New York Heart Association (NYHA) functional classificat

290 and reduced ejection fraction, in particular New York Heart Association (NYHA) I-II.

291 (A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure

292 investigated in 1245 patients (>/=60 years; New York Heart Association [NYHA] class II-IV, ischemic

293 tomatic at the time of index echocardiogram (New York Heart Association [NYHA] functional class II: 4

294 onitoring of Pressure to Improve Outcomes in New York Heart Association [NYHA] Functional Class III H

295 onitoring of Pressure to Improve Outcomes in New York Heart Association [NYHA] Functional Class III H

296 changes in standard functional assessments (New York Heart Association, quality of life, 6-minute wa

297 The New York Heart Association score was >/= 2 in 41 partici

298 ent status (6% versus 4%, P=0.01), and worse New York Heart Association status (P<0.001).

299 New York Heart Association symptom class was improved or

300 omized patients with atrioventricular block, New York Heart Association symptom classes I to III HF,